Litigation Details for IBSA INSTITUT BIOCHIMIQUE SA v. ACCORD HEALTHCARE, INC. (D.N.J. 2023)

IBSA INSTITUT BIOCHIMIQUE SA v. ACCORD HEALTHCARE, INC. (D.N.J. 2023)

Docket	2:23-cv-00054	Date Filed	2023-01-05
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	James B. Clark III
Parties	ACCORD HEALTHCARE, INC.
Patents	10,537,538; 11,096,913; 11,241,382; 9,345,772
Attorneys	ALEXANDER LEE CALLO
Firms	Saul Ewing LLP
Link to Docket	External link to docket

Details for IBSA INSTITUT BIOCHIMIQUE SA v. ACCORD HEALTHCARE, INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-05				External link to document

Litigation summary and analysis for: IBSA INSTITUT BIOCHIMIQUE SA v. ACCORD HEALTHCARE, INC. (D.N.J. 2023)

Last updated: July 26, 2026

IBSA v. Accord Healthcare (2:23-cv-00054) | Litigation summary, claims at issue, procedural posture, and likely patent-expiration impact

Executive summary: The case IBSA Institut Biochimique SA v. Accord Healthcare, Inc. (D.N.J., No. 2:23-cv-00054) is a Hatch-Waxman patent infringement action brought by IBSA against Accord Healthcare tied to a generic launch challenge involving IBSA’s branded product(s). The docket supports a typical ANDA Paragraph IV framework: IBSA alleges Accord’s filing infringes one or more Orange Book-listed patents, and Accord’s response centers on non-infringement and invalidity. This filing date places the dispute squarely inside the window where 180-day exclusivity, settlement timing, and patent expiration (including later-expiring formulation or method-of-use patents) can control the timing of generic entry.

---

What is the patent infringement case IBSA v. Accord Healthcare (2:23-cv-00054) about?

Featured-snippet answer: The matter is a Hatch-Waxman ANDA patent litigation in which IBSA asserts Orange Book patents against Accord over a generic product that seeks FDA approval while the asserted patents are still in force.

Parties and forum

• Plaintiff: IBSA Institut Biochimique SA
• Defendant: Accord Healthcare, Inc.
• Court: U.S. District Court for the District of New Jersey (D.N.J.)
• Case number: 2:23-cv-00054
• Case type: Patent infringement under the Hatch-Waxman Act (commonly tied to ANDA Paragraph IV)

Core legal theory (typical structure in this posture)

• IBSA identifies patents listed in the Orange Book for its branded drug.
• Accord’s ANDA is alleged to fall within the scope of one or more claims.
• Accord counters with defenses in the usual categories:
  • non-infringement
  • invalidity (anticipation, obviousness, lack of enablement, indefiniteness where applicable)
  • procedural defenses tied to notice and statutory requirements

---

Which patents does IBSA assert in 2:23-cv-00054 and what are the claim categories?

Featured-snippet answer: The docket-centered summary is that IBSA asserts Orange Book-listed patents, which in Hatch-Waxman cases usually include at least one of the following:

• composition/formulation patents (drug substance, dosage form, excipients, stability, solid state forms)
• method-of-use patents (indication, dosing regimen, patient population)
• manufacturing or process patents (when separately Orange Book-listed)

How to map the asserted patent estate to litigation leverage

For Hatch-Waxman cases like this, the most business-relevant way to analyze the patent estate is by “lifespan value”:

• Earliest-expiring patent controls the first potential entry date if invalidated or designed around.
• Later-expiring formulation/method patents often become the real hold-up because they survive longer and can extend exclusivity-like leverage even after earlier patents fall.
• Process patents can matter less for generic entry if the ANDA product is already aligned to a known manufacturing route, but they can still create licensing leverage if the claimed process is specific.

Table: patent estate categories and litigation impact

Patent category (common in Orange Book listings)	What IBSA typically claims	What Accord typically challenges	Business effect if asserted patent falls
Composition/formulation	Specific drug composition, dosage form, excipient system, stability/solid state	Claim construction limits, lack of overlap, invalidity (prior art/obviousness)	Enables at-scale generic launch if still no other blocking patents
Method of use	Indication/dosing regimen	Non-infringement based on label carve-outs and ANDA description; invalidity	Limits launch to non-covered uses; can force “skinny label”
Manufacturing/process	Specific steps/parameters	Infringement by equivalence is constrained by product-specific ANDA description; invalidity	Can block launch or require licensed manufacturing route

---

What procedural steps and briefing schedule likely drive outcomes in IBSA v. Accord?

Featured-snippet answer: The litigation follows the standard Hatch-Waxman progression: pleadings, claim construction, infringement/invalidity contentions, discovery, claim construction order, then dispositive motions and pretrial filings.

Key litigation phases that decide market timing

Even without a settlement outcome, the procedural milestones in D.N.J. are what move the case toward either (a) a final invalidity/infringement decision or (b) a settlement with defined launch terms.

Table: milestone to decision linkage

D.N.J. phase	What it determines	Why it matters for exclusivity and entry
Pleadings and infringement contentions	Scope of asserted claims and accused product theory	Sets whether Accord’s “design around” is viable
Claim construction (Markman)	Meaning of claim terms	Often collapses infringement/invalidity coverage fast
Expert discovery and technical claim charts	Whether the ANDA product maps to each limitation	Drives settlement valuation or trial posture
Summary judgment (if filed)	Early end to liability	Can accelerate generic launch date
Trial (rare if patents settle)	Final infringement/validity	Sets legal end-state for future generic entrants

---

When does the 180-day exclusivity window matter in this case, and how can it shift leverage?

Featured-snippet answer: This case is filed in 2023, so 180-day exclusivity (if Accord is the first Paragraph IV filer for the product) becomes a critical bargaining chip and can control the economic settlement value independent of ultimate patent strength.

Exclusivity mechanics that commonly affect settlement amounts

In Hatch-Waxman, exclusivity can be triggered or forfeited by:

• timing of first Paragraph IV certification
• approval and launch actions
• failure to market “commercially reasonable efforts”
• changes in listed patents that alter “trigger” calculations

Business implication: Even if multiple patents are asserted, the party that can credibly claim exclusivity leverage usually demands a defined entry date and/or carve-outs.

---

How strong is the patent estate for IBSA versus Accord’s generic design-around options?

Featured-snippet answer: The strength of an Orange Book estate is rarely measured by raw number of patents; it is measured by claim coverage breadth after claim construction and the likelihood of surviving invalidity challenges based on cited prior art.

Litigation risk framework used in renewables-style portfolio assessments

For each asserted patent, the valuation model typically weights:

• how narrow the claim language becomes under the court’s claim construction
• how directly the generic product’s ingredients/formulation/process aligns to each limitation
• whether obviousness arguments rely on a single reference or multiple references with a motivation to combine
• whether secondary considerations exist (commercial success, long-felt but unsolved need, copying) and whether they are supported by record evidence

Table: risk flags that can change the settlement range

Risk factor	If present, it increases…	Litigation effect
Tight claim limitations tied to specific excipients/ratios	Accord probability of non-infringement	Settlement pressure increases for IBSA
Prior art closest-reference published years earlier	Accord invalidity probability	Court may narrow enforceability fast
Overlapping dependent claims	IBSA resilience	Even if independent claim fails, dependent claims can survive
Narrowness of method-of-use label	Accord likely “skinny label” pathway	Infringement can be avoided through label changes

---

What is the Orange Book status of IBSA’s drug(s) in relation to Accord’s ANDA?

Featured-snippet answer: The case implies IBSA has at least one Orange Book-listed patent triggered by Accord’s ANDA certification, which is the legal predicate for filing a Paragraph IV infringement suit.

How to interpret Orange Book status for litigation leverage

• Patent listed as drug substance vs drug product often correlates with claim category.
• Later-expiring patents can function as de facto exclusivity extension because they remain enforceable even if earlier patents drop.
• Multiple patents tied to one NDA typically create a cumulative settlement environment.

---

How does IBSA’s case strategy compare with other D.N.J. Hatch-Waxman litigations against Accord?

Featured-snippet answer: The D.N.J. forum and the accused-party profile indicate a strategy consistent with other brand-to-generic contests: focus on enforceable, claim-constructable limitations that map cleanly to the ANDA product description and the likely generic formulation.

What brand plaintiffs usually do in this posture

• Anchor infringement to claim terms that are hard to design around (specific formulation attributes, required performance characteristics).
• Use method-of-use claims selectively when label carve-outs are difficult or commercially undesirable.
• Pair formulation and method claims when the goal is to reduce the feasibility of “skinny label” entry.

---

What generic entry risks exist for Accord if it loses on infringement or invalidity?

Featured-snippet answer: If Accord is found to infringe and patents are upheld, generic entry is blocked until patent expiration of the last unexpired asserted patent, absent a settlement or design-around that is not covered by the final injunction scope.

Market timing chain

1. If IBSA wins on at least one asserted patent: injunction typically follows.
2. Generic entry can be delayed until the earliest-to-expire among the surviving patents.
3. Settlement can convert a block into a future entry date tied to partial patent allowance or covenant terms.

---

What settlement terms typically arise in IBSA-style Hatch-Waxman cases like this?

Featured-snippet answer: Settlements in this posture usually include a negotiated entry date, sometimes with carve-out language tied to noninfringing formulations or specific label restrictions.

Settlement term patterns

• agreed launch date (often a function of the last surviving patent expiration)
• stipulation to dismiss claims with/without prejudice
• “covenant not to sue” covering a defined product configuration
• dismissal of appeals with specified timing

Business impact: the settlement economics track the “real blocking patent” rather than the full asserted list.

---

How do biosimilar or biologic exclusivity concepts factor in a case like this?

Featured-snippet answer: No biosimilar framework is indicated by the case caption alone; this case is framed as an ANDA patent infringement action against a small-molecule generic maker.

Why this matters

• Biosimilar exclusivity and BPCIA timelines differ materially from Hatch-Waxman.
• This posture is aligned to ANDA Orange Book patent triggers and 180-day exclusivity mechanics.

---

Key case analytics: what drives the likely outcome in 2:23-cv-00054?

Featured-snippet answer: Outcomes typically hinge on (a) claim construction narrowing, (b) prior art strength for invalidity, and (c) whether Accord’s ANDA product maps to all claim limitations as construed.

Litigation drivers table

Driver	Typical evidentiary source	Outcome direction if IBSA proves it
Claim construction favorable to brand	court order; intrinsic evidence	increases infringement probability
Infringement proof based on ANDA composition/specs	ANDA description, stability, bioequivalence linkage	increases liability risk for Accord
Invalidity rejected (no teaching, no motivation, secondary evidence)	expert testimony, prior art mapping	increases injunction likelihood
Label-controlled method-of-use claims not avoidable	ANDA labeling, FDA-approved labeling structure	reduces “skinny label” options

---

Timeline of the case (what to track operationally)

Featured-snippet answer: The practical timeline is anchored by filing in 2023, then progresses through Markman and dispositive motion windows, with the commercially relevant inflection points being claim construction and any settlement milestones.

Date (relative)	What typically happens	Market relevance
2023 filing	Complaint, infringement contentions served	sets the barrier to entry
Pre-Markman phase	discovery, document production	starts technical mapping
Markman	claim terms construed	often determines whether trial is inevitable
Dispositive motion window	summary judgment	can accelerate launch date or end case
Pretrial and trial	merits adjudication	final injunction/validity outcome

---

How does IBSA v. Accord (2:23-cv-00054) affect downstream generic licensing and future Paragraph IV entrants?

Featured-snippet answer: The case can deter subsequent entrants if the litigation resolves core claim constructions or if any surviving patents are later enforced against others. It can also make licensing more attractive if IBSA obtains or threatens injunction leverage.

Portfolio and competition effect

• If asserted patents survive, later generics face the same blocking limitations and must wait or license.
• If claim construction narrows or invalidity is sustained, subsequent entrants can pursue faster design-around strategies.

---

Key Takeaways

• IBSA v. Accord Healthcare, 2:23-cv-00054 is a Hatch-Waxman ANDA Paragraph IV infringement dispute in D.N.J. with IBSA asserting Orange Book-listed patents.
• The case’s commercial significance is driven by which patent(s) survive claim construction and invalidity challenges, and by whether 180-day exclusivity and settlement timing control entry.
• In Hatch-Waxman practice, the economic outcome often turns on whether the ANDA product matches claim limitations as construed, especially for formulation and/or method-of-use claims.
• Even without a final merits result in a quick docket view, the procedural milestones (Markman, dispositive motions) are the inflection points for whether generic entry is blocked until later-expiring patents or can proceed via design-around and/or settlement.

---

FAQs

1) What happens to generic exclusivity if the first Paragraph IV filer loses the case?

The 180-day exclusivity can be affected by forfeiture or failure to satisfy statutory conditions, and downstream entrants may rely on their own eligibility if exclusivity is not preserved.

2) Can Accord launch “at risk” during litigation in a case like 2:23-cv-00054?

Typically, if a court enters or is expected to enter injunctive relief tied to surviving asserted patents, “at risk” launch is blocked practically and legally.

3) Do formulation patents or method-of-use patents usually dominate settlement value in D.N.J. ANDA cases?

Formulation and method patents dominate when they cover core technical attributes that are hard to avoid without changing the product or label.

4) How do claim construction outcomes usually shift settlement leverage?

A favorable Markman for the brand can strengthen infringement positions and raise the cost of litigating invalidity. A narrowing construction can reduce the infringement surface area and increase settlement pressure.

5) If one asserted patent is invalidated, does it end the case automatically?

Not necessarily; other asserted patents can remain, and the case proceeds based on the surviving claims unless fully disposed of by final judgments or settlements.

---

References

1. Case docket, IBSA Institut Biochimique SA v. Accord Healthcare, Inc., No. 2:23-cv-00054 (D.N.J.).